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Abstract: The management of Helicobacter pylori infection has to rely on previous local effective-
ness due to the geographical variability of antibiotic resistance. The aim of this study was to
evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empir-
ical prescription is recommended. A multicentre prospective non-interventional registry of the
clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was
developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively
and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump in-
hibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included,
and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day
bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day
bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day
non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies.
Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple
quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple
schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effective-
ness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration
and higher acid inhibition were associated with higher effectiveness. “Optimized” H. pylori therapies
achieve over 90% success in Spain.
Keywords: Helicobacter pylori; treatment; first-line; second-line; Spain
1. Introduction
Helicobacter pylori (H. pylori) is a gram-negative bacterium with an estimated prevalence
in southern Europe of 50%, involved in several important diseases such as chronic gastritis,
peptic ulcer disease and gastric cancer, as well as in some important extra-gastric diseases
such as iron deficiency anaemia or idiopathic thrombocytopenic purpura, among others [1–5].
These two factors are enough to explain the importance of finding a successful therapy
able to eliminate the bacterium with the least amount of antibiotic treatment attempts. This
is especially important considering the effect of antibiotics on the patient’s gut microbiota
and the emergence of multi-resistant bacterial strains worldwide [6–8].
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However, an effective global treatment has not been found. Although several factors
might be considered, the geographical variability of antibiotic resistance among different
H. pylori strains (due to previous antibiotic exposure of both the patient and the community)
represents an important obstacle, especially considering the extended recommendation
of using empirical prescriptions [1,9,10]. In this sense, clarithromycin, metronidazole and
levofloxacin, antibiotics frequently used against H. pylori, have shown at least moderate
resistance rates in southern Europe and specifically in Spain, which has justified the
emergence of numerous and varied optimization strategies [9,11,12].
With the aim of obtaining updated information on H. pylori treatment in Spain and to




In total, 53 Spanish hospitals were selected (Supplementary Materials Figure S1) and
14,128 patients were included for the descriptive demographic analysis (Table 1).
Table 1. Baseline characteristics of first- and second-line treatments.
Variables Overall N (%) 1st Line N (%) 2nd Line N (%)
14,128 10,633 2481
Gender
Female 8795 (62) 6477 (61) 1632 (66)
Male 5320 (38) 4146 (39) 847 (34)
Age, mean (standard deviation) 50 ± 15 51 ± 14.7 50 ± 14.5
Penicillin allergy Presence 644 (4.6) 435 (4.1) 151 (6.1)
Indication
Dyspepsia 9152 (65) 6823 (64) 1656 (67)
Ulcer disease 2103 (15) 1554 (15) 393 (16)
Others 2868 (20) 2251 (21) 432 (17)






No resistance 199 (54)
Clarithromycin R 52 (14)
Metronidazole R 93 (25)
Clarithromycin and
metronidazole R 18 (4.9)
Levofloxacin R 63 (17)
Treatment length
7 days 182 (1.3) 160 (1.5) 17 (0.7)
10 days 8615 (61) 6670 (63) 1382 (56)
14 days 5273 (37) 3764 (35) 1074 (43)
Others 58 (0.4) 39 (0.4) 8 (0.3)
Proton pump inhibitor dose
Low 5110 (37) 4063 (39) 751 (31)
Standard 3290 (24) 2605 (25) 458 (19)
High 5496 (39) 3834 (36) 1239 (50)
Compliance
No (<90% drug intake) 415 (2.9) 304 (3) 69 (2.8)
Yes (≥90% drug intake) 13,159 (93) 9932 (93) 2302 (92.8)
Unknown 554 (3.9) 397 (4) 110 (4.4)
N, total of patients included; %, proportion of patients included; R, resistance; NA, not applicable; Low, ≈20 mg omeprazole equivalents
b.i.d.; Standard, ≈40 mg omeprazole equivalents b.i.d.; High, ≈60 mg omeprazole equivalents b.i.d.
2.2. Treatment Use and Effectiveness
2.2.1. First-Line Treatment
A total of 10,267 patients received an empirical first-line treatment. The most fre-
quently prescribed regimens were: non-bismuth quadruple concomitant therapy (PPI-
clarithromycin-amoxicillin-metronidazole, all four drugs administered concomitantly,
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n = 4051, 40%), standard triple regimen (PPI-clarithromycin-amoxicillin, n = 2712, 26%),
bismuth quadruple therapy (bismuth single-capsule, marketed as Pylera® (Allergan, Inc
Dublin, IE) containing tetracycline-metronidazole-bismuth salts administered together
with a PPI, n = 1660, 16%), bismuth-clarithromycin quadruple therapy (PPI-clarithromycin-
amoxicillin-bismuth, n = 1055, 10%), non-bismuth sequential quadruple regimen (PPI-
amoxicillin during five days, followed by PPI-clarithromycin-metronidazole during the
five remaining days, n = 230, 2.2%) and clarithromycin-metronidazole triple therapy (PPI-
clarithromycin-metronidazole, n = 124, 1.2%). The prescription trends over time, as shown
in Figure 1.
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Overall effectiveness of the first-line therapies reached 88% on the mITT analysis. The 
highest effectiveness was obtained with the bismuth single-capsule (95%), the bismuth-
clarithromycin therapy (91%) and the concomitant therapy (90%) (Table 2). Adverse 
events (AE) appeared in 25% of the patients; however, most of them were of mild intensity 
(62%) and only 0.2% of the patients presented a serious AE. Compliance was higher than 
97% (see Table S1 and File S2 for a detailed analysis of safety). 
Figure 1. Prescription trends in first- (A) Type of therapy; (B) Duration of therapy; (C) Dose of PPI and second-line (D)
Type of therapy; (E) Duration of therapy; (F) Dose of PPI treatment. PPI: proton-pump inhibitor, C: clarithromycin, A:
amoxicillin, M: metronidazole, Single-capsule: three-in-one single capsule, Bi: bismuth, Conc: concomitant administration,
Seq: sequential administration, L: levofloxacin, Mx: Moxifloxacin, Low: ≈20 mg omeprazole equivalents b.i.d., Standard:
≈40 mg omeprazole equivalents b.i.d., High: ≈60 mg omeprazole equivalents b.i.d.
Overall effectiveness of the first-line therapies reached 88% on the mITT analysis. The
highest effectiveness was obtained with the bismuth single-capsule (95%), the bismuth-
clarithromycin therapy (91%) and the concomitant therapy (90%) (Table 2). Adverse events
(AE) appeared in 25% of the patients; however, most of them were of mild intensity (62%)
and only 0.2% of the patients presented a serious AE. Compliance was higher than 97%
(see Table S1 and File S1 for a detailed analysis of safety).
The overall multivariate analysis performed with the first-line treatment showed that
higher effectiveness was associated with good compliance (OR = 4.1; 95% CI: 3.0–5.5),
extended therapies (10 days (OR = 4.5; 95% CI: 3.2–6.2) or 14 days length (OR = 4.1; 95% CI:
2.9–5.9)), higher gastric acid inhibition (standard (OR = 1.4; 95% CI: 1.2–1.7) or high PPI
doses (OR = 2.1; 95% CI: 1.7–2.4)), presence of peptic ulcer (OR = 1.2; 95% CI: 1.0–1.5) and
male gender (OR = 1.2; 95% CI: 1.1–1.4) (see Table 3 for the analysis of each therapy).
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Table 2. Effectiveness, safety and compliance of the most frequent therapies prescribed in the first- and second-line treatments.
Effectiveness Adverse Events Compliance
Treatment ITT mITT PP
N (%) 95% CI N (%) 95% CI N (%) 95% CI N (%) 95% CI N (%) 95% CI
1st line 10,101 (83.5) 83–84 9726 (88) 88–89 9497 (89) 88–89 9937 (25) 25–26 9886 (97) 96–97
PPI + C + A + M (Conc) 3996 (86) 85–87 3880 (90) 89–91 3781 (90) 89–91 3963 (28) 26–29 3942 (97) 96–97
PPI + C + A 2712 (78) 76–80 2544 (83) 82–85 2498 (84) 82–85 2617 (15) 13–16 2598 (98) 97–98
PPI + Single–capsule 1574 (88) 86–89 1540 (95) 94–96 1514 (96) 95–97 1566 (25) 23–27 1562 (97) 96–98
PPI + Bi + C + A 1034 (88) 86–90 1015 (91) 89–93 1002 (91) 89–93 1019 (40) 37–44 1021 (98) 98–99
PPI + C + A + M (Seq) 230 (79) 73–84 222 (81.5) 76–86 192 (84) 79–89 230 (49) 42–55 222 (86.5) 81–91
PPI + C + M 124 (59) 50–68 113 (65) 55–73 112 (65) 65–74 119 (16) 10–24 118 (97.5) 93–99
2nd line 2420 (79) 77–80 2295 (84) 82–85 2247 (84) 82–86 2348 (28) 27–30 2342 (97) 96–98
PPI + L + A 944 (74) 71–77 893 (78.5) 76–81 881 (79) 76–82 919 (26) 23–29 908 (99) 98–99
PPI + Bi + L + A 463 (86) 83–89 451 (89) 86–92 435 (90) 87–93 454 (33) 28–37 459 (95) 93–97
PPI + Single–capsule 443 (80) 76–84 409 (88) 85–91 398 (89) 85–92 422 (31) 27–36 420 (96) 94–98
PPI + Mx + A 135 (87) 80–92 129 (91) 84–95 129 (91) 84–95 134 (19) 13–27 133 (99) 96–100
PPI + C + A + M (Conc) 120 (74) 65–82 110 (82) 73–89 109 (82) 73–88 112 (24) 17–33 112 (98) 94–100
ITT, intention-to-treat; mITT, modified intention-to-treat; PP, per protocol; N, total of patients included; %, proportion of patients presenting effectiveness/adverse events/compliance; CI, confidence interval; PPI,
proton pump inhibitor; C, clarithromycin; A, amoxicillin; M, metronidazole; Single-capsule, three-in-one single capsule; Bi, bismuth; L: levofloxacin; Mx, moxifloxacin; Conc, concomitant administration; Seq,
sequential administration.
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Table 3. Multivariate analysis of patients treated with a first-line therapy.
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Compliance [R: <90% DI] 1 1 1 1 1 1











Overall, the population receiving a first-line therapy; PPI, proton pump inhibitor; C, clarithromycin; A, amoxicillin; M, metronidazole; Single-capsule, three-in-one single capsule; Bi, bismuth; Conc, concomitant
administration; Seq, sequential administration; OR, odds ratio; CI, confidence interval; R, category of reference used for the logistic regression; OE, omeprazole equivalent; DI, drug intake; NA, not applicable; †
99.7% of the patients received 10-days of therapy so comparison in length terms was not possible; ‡ 99.6% of the patients received 10-days of treatment so comparison in terms of length was not possible.
Antibiotics 2021, 10, 13 7 of 15
2.2.2. Second-Line Treatment
A total of 2448 patients received an empirical second-line therapy. Five therapies
were most frequently used: the levofloxacin-amoxicillin triple therapy (PPI-amoxicillin-
levofloxacin, n = 944, 39%), the bismuth-levofloxacin quadruple therapy (PPI-amoxicillin-
levofloxacin-bismuth, n = 475, 19.4%), the bismuth single-capsule (n = 454, 18.6%), the
moxifloxacin-amoxicillin therapy (PPI-amoxicillin-moxifloxacin, n = 136, 5.6%) and the
concomitant therapy (n = 121, 4.9%). Treatment prescriptions over time are depicted in
Figure 1.
Overall effectiveness of second-line therapies reached 84% on the mITT analysis.
Highest effectiveness was obtained with the bismuth-levofloxacin therapy (89%) and the
bismuth single-capsule (88%) (Table 2). AE were reported in 28% of the cases (49% and 47%
of them being of moderate and mild intensity, respectively, and only one patient showing
a serious AE). Compliance was higher than 95% (see Table S1 and File S1 for a detailed
analysis of safety).
The overall multivariate analysis performed with second-line treatment showed that
higher effectiveness was associated with good compliance (OR = 3.4; 95% CI: 1.7–6.9), high
PPI dose (OR = 1.9; 95% CI: 1.4–2.6) and 14-day therapy (OR = 1.5; 95% CI: 1.1–2.1) (See
Table 4 for the analysis of separated therapies considering only the three therapies more
frequently used in second-line in Spain).
Effectiveness by treatment duration and PPI doses in first- and second- line regimens
are shown in Tables S2 and S3.
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Table 4. Multivariate analysis of patients treated with a second-line therapy.










[R: Female] 1 1 1 1
Male 1.39 (1.07–1.81) 0.014 1.03 (0.70–1.50) 0.898 2.83 (1.33–6.05) 0.007 0.96 (0.47–1.93) 0.898
Age
[R: 18–30] 1 1 1 1
31–50 0.60 (0.36–0.99) 0.045 0.81 (0.39–1.70) 0.582 0.64 (0.17–2.34) 0.506 0.33 (0.07–1.52) 0.156
51–70 0.44 (0.27–0.73) 0.001 0.47 (0.23–0.97) 0.041 0.36 (0.10–1.29) 0.118 0.38 (0.08–1.73) 0.211
≥71 0.37 (0.20–0.69) 0.002 0.43 (0.18–1.03) 0.059 0.24 (0.05–1.09) 0.064 0.73 (0.09–5.82) 0.766
Presence of
ulcer
[R: No] 1 1 1 1
Yes 1.07 (0.74–1.54) 0.729 1.04 (0.63–1.73) 0.869 1.97 (0.44–8.76) 0.374 0.79 (0.32–1.94) 0.600
Previous C
[R: No] 1 1 1
NA †Yes 0.63 (0.33–1.21) 0.167 0.82 (0.16–4.12) 0.809 0.21 (0.03–1.79) 0.155
Length [R: 10] 1 1 1
14 1.51 (1.11–2.05) 0.009 3.88 (2.24–6.71) 0.000 3.12 (0.35–27.6) 0.307 0.64 (0.07–5.93) 0.692
PPI dose of OE
[R: Low] 1 1 1 1
Standard 1.21 (0.88–1.65) 0.241 1.20 (0.81–1.79) 0.360 2.50 (0.40–15.5) 0.325 1.45 (0.56–3.77) 0.443
High 1.88 (1.37–2.59) 0.000 1.66 (0.99–2.77) 0.055 3.24 (1.09–9.59) 0.034 1.43 (0.72–2.87) 0.310
Compliance [R: <90% DI] 1 1 1 1≥90% DI 3.43 (1.71–6.88) 0.001 5.47 (1.27–23.5) 0.023 3.01 (0.91–9.99) 0.071 4.46 (1.02–19.5) 0.047
Overall, the population receiving a second-line therapy; PPI, proton pump inhibitor. L, levofloxacin; A, amoxicillin; Bi, bismuth; Single-capsule, three-in-one single capsule; OR, odds ratio; CI, confidence interval;
R, category of reference used for the logistic regression; C, clarithromycin; OE, omeprazole equivalent; DI, drug intake; NA, not applicable; †96% of the patients had previously received clarithromycin so
comparison between both groups was not possible.
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2.3. Penicillin Allergic Patients
A total of 411 patients allergic to penicillin received an empirical first-line therapy,
being the most frequent, the bismuth single-capsule (n = 154, 37.5%) and the clarithromycin-
metronidazole therapy (n = 117, 28.5%). The overall effectiveness was 81% in first-line,
although the bismuth single-capsule reached 94% mITT effectiveness. A second-line
attempt was empirically used in 137 patients allergic to penicillin, being the bismuth
single-capsule (n = 34, 24.8%), the most frequently used.
Results on effectiveness, safety and compliance as well as effectiveness stratified by
length and PPI dose, are shown in Tables S4–S6.
3. Discussion
Treatment of H. pylori infection in Spain in first- and second- line, in which the empiri-
cal approach is generally recommended, still remains a challenge, especially considering
the more demanding threshold of effectiveness required lately (90%) [6]. This has led
to the progressive complexity of the regimens prescribed, which involve an increasing
use of quadruple regimens, longer prescriptions (10–14 days) and higher PPI doses over
time [1,9].
Concerning first-line treatment, we found an overall effectiveness of 88% in our cohort,
close to the optimal threshold required, combined with an optimal safety profile [6,13].
Analysis of each specific therapy revealed that the standard triple therapy containing
clarithromycin and amoxicillin, recommended throughout several years in Spain, only
reached approximately 80% success, in line with previous evidence [14]. Its low effective-
ness, together with the increasing clarithromycin resistance rates over time (up to 20%
recently notified) led to the discontinuation of its use in our area [6,9,12]. This drop in
prescriptions over time in our cohort brought with it the increase of use of quadruple thera-
pies, such as the concomitant, the bismuth single-capsule and the bismuth-clarithromycin
therapies, which also were, precisely, the therapies showing the highest effectiveness
(≥90%).
Concomitant treatment was the therapy most frequently used in first-line, in agree-
ment with recommendations provided by national guidelines [9]. This therapy showed
90% effectiveness, similar to previous reports, and was mostly due to the relatively low
dual resistance rates to both clarithromycin and metronidazole documented in our coun-
try [9,12,15–17]. With regard to the bismuth-clarithromycin quadruple therapy, a progres-
sive rise on its prescription was seen over time, and it showed a very high effectiveness
(91%), similar to previous evidence [18]. In fact, data coming from areas with higher
clarithromycin resistance than Spain such as China still show high success of this therapy,
which is thought to be at least partially compensated by the use of bismuth [19]. This is
encouraging, assuming a hypothetical increase of clarithromycin resistance in Spain in the
following years. The use of a bismuth quadruple therapy that contains tetracycline and
metronidazole also avoids the problem of clarithromycin resistance due to the absence
of this antibiotic and the low probability of developing resistance to components such
as bismuth or tetracycline by H. pylori [9,20]. Moreover, the commercialization of a pill
containing the three aforementioned drugs facilitated the access to tetracycline, which used
to be hardly available in this area [9,21]. This therapy showed an eradication rate of 95% in
our cohort, similar to what was described in a recently published meta-analysis [22].
When we analysed the variables associated with the increase of effectiveness, good
compliance (≥90% of drug intake) showed the highest association for overall treatment
and also for nearly all the therapies analysed individually. Other authors had previously
reported this association [17,18,23,24]. Therefore, strategies designed to pursue the best
compliance possible are needed.
The use of standard PPI doses (≈40 mg omeprazole equivalents b.i.d.) or high PPI
doses (≈60 mg omeprazole equivalents b.i.d.) showed higher effectiveness in our cohort in
the overall analysis and in the concomitant, bismuth-clarithromycin and bismuth single-
capsule therapies. Previous reports had already shown a beneficial effect of higher grades
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of gastric acid inhibition on the eradication treatment, especially in amoxicillin-containing
therapies, considering the higher susceptibility of H. pylori to amoxicillin in a less acidic
environment. This is particularly important for the treatment of clarithromycin-resistant
strains [17,18,24,25]. The finding of this increase in effectiveness with the bismuth single-
capsule is remarkable, as other authors reported an absence of association [22]. Although
an adjuvant effect of high PPI doses in metronidazole resistant strains has been suggested,
specific studies on this issue are strongly encouraged [26].
Increasing the length of therapy (10 or 14 days instead of 7) also increased overall
effectiveness in our first-line cohort. The three quadruple therapies showing highest
effectiveness were compared between 10 and 14-days (7-day treatment was excluded from
analysis in these therapies because of the small number of patients included). While the
concomitant therapy showed a tendency towards better results with the longest duration
in accordance with previous reports [15], neither of the two remaining quadruple therapies
(both containing bismuth) showed association between treatment length and effectiveness
in our study. However, it is important to clarify that prescriptions were made for 10 days
in the bismuth single-capsule and for 14 days in the bismuth-clarithromycin therapy in
99% of the cases, which could have limited the comparisons.
The overall effectiveness of second-line attempts was 84% in our cohort, close but
not reaching the 90% of threshold previously mentioned. The prescription of second-line
therapies in our cohort has evolved over time similarly to what happened in the first-line:
in this case, quinolone-containing triple therapies experienced a decrease of use while
quadruple regimens experienced the opposite (i.e., bismuth-levofloxacin quadruple therapy
or the bismuth single-capsule) [9].
The levofloxacin-amoxicillin triple therapy has been one of the most traditionally
employed regimens in rescue attempts in Spain, based on the previously considered
“acceptable” results (showing around 80% effectiveness in our cohort) [27]. Although
this rate is currently considered unacceptable, the increase of treatment duration up to 14
days led to a 92% effectiveness (similar to the findings obtained in areas with levofloxacin
resistance rates similar to Spain) making it still an interesting alternative to consider [28].
Something similar happened with the moxifloxacin-amoxicillin therapy, which showed 91%
effectiveness in our cohort, a figure markedly higher than that reported by other authors
(78–82%) [29,30]. These studies included high doses of PPI and a 14-day duration, similar
to the majority of the prescriptions made in our cohort. Updated evidence concerning both
quinolone-containing triple therapies is needed before definitive conclusions are drawn.
However, triple levofloxacin-based therapies suffer the limitation of the increasing
resistance to quinolones worldwide [11]. In order to overcome this resistance, bismuth
has been added to the levofloxacin-amoxicillin therapy, forming the quadruple therapy
previously described. This therapy achieved around 90% effectiveness in our cohort, in
accordance with previous studies [31,32]. It is important to remark that more than 90% of
the prescriptions had 14-day lengths and used high PPI doses, which could have increased
the effectiveness per se. In addition, it is important to remember that the local cut-off
point of quinolone resistance for cost-effectiveness of this quadruple therapy has yet to be
established.
The use of bismuth single-capsule has provided effectiveness around 90% concerning
rescue attempts, representing an interesting alternative rescue-treatment to consider [22].
More than 98% of the prescriptions in our study were made for a 10-day duration, following
the currently recommended dosage.
In our cohort, the effectiveness of clarithromycin-containing triple therapies with
either metronidazole or levofloxacin was suboptimal in the allergic to penicillin population,
in agreement with previously published evidence [33]. The use of the bismuth single-
capsule in this setting has markedly increased effectiveness, achieving up to 94% in our
cohort in first-line treatment, thus confirming this regimen as the current therapy of choice
in this population [1,9,34].
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Despite these relevant findings, our study has several limitations. The main one is the
low proportion of patients subjected to culture testing. It is unquestionable that promoting
the creation of big-size databases to update local antibiotic resistance information could
improve effectiveness. Nonetheless, the current study was developed to evaluate the rou-
tine practice of gastroenterologists in Spain, where the empirical prescription is generally
advocated up to three eradication attempts [9]. Another limitation of the present study
is its observational design, with the consequent potential higher risk of bias. However,
the large size of our sample (including more than 10,000 patients in first line) should have
compensated for this limitation. Due to the source of the data (concerning real updated
information from routine clinical practice in Spain), our study provides a comprehensive
global overview of the current local management, whose conclusions are easily applicable
in routine practice.
4. Materials and Methods
This study is a sub-analysis focused on the Spanish centres actively participating
in the “European Registry on H. pylori Management” (Hp-EuReg), an international
(27 countries), multicentre (300 investigators), prospective non-interventional registry that
started in 2013 and promoted by the European Helicobacter and Microbiota Study Group
(www.helicobacter.org) [35]. The established Scientific Committee, national coordinators,
gastroenterologist recruiting investigators and a list of variables and outcomes are detailed
in the previously published protocol [36]. This protocol was approved by the Research
Ethics Committee of La Princesa University Hospital (Madrid, Spain) and prospectively
registered at ClinicalTrials.gov (NCT02328131). Written informed consent was obtained
from each patient included in the study.
Data were recorded in an Electronic Case Report Form (e-CRF), collected and managed
using REDCap, and were subjected to quality review. REDCap is an electronic data capture
tool hosted at “Asociación Española de Gastroenterología” (AEG; www.aegastro.es), a
non-profit scientific and medical society focused on gastroenterology research [37,38].
The aim of the current sub-analysis was to evaluate in the Hp-EuReg the effectiveness
of first and second-line treatments in Spain. Secondary aims included the evaluation of
strategies designed to increase effectiveness, prescription trends over time, and safety.
4.1. Variables
The e-CRF registered 290 variables including demographics, comorbidity, data on
infection and diagnosis, previous eradication attempts, current treatment, compliance, AE
and effectiveness [36]. The variable treatment length was assessed using three categories
for first-line therapies, corresponding with the most frequent treatment durations: 7, 10
and 14 days; and two categories for second-line attempts: 10 and 14 days. The variable
dose of the proton pump inhibitor (PPI) was grouped in three categories (low, standard
and high doses) according to reports by Graham and Kirchheiner [25,39] (See File S2).
4.2. Effectiveness Analysis
H. pylori eradication was confirmed with at least one of the following diagnostic
methods: urea breath test, stool antigen test and/or histology; at least one month after
completing eradication treatment. The treatment eradication rate was the main outcome
and was studied in three sets of patients as follows: intention-to-treat (ITT) analysis
included all patients registered up to June 2019, to allow at least a 6-month follow-up,
and lost to follow-up cases were considered treatment failures. Per-protocol (PP) analysis
included all cases that finished follow-up and had taken at least 90% of the treatment drugs.
A modified ITT (mITT) analysis was designed aiming to reach the closest result to clinical
practice, including all cases that had completed follow-up (that is, a confirmatory test of
success or failure was available after eradication treatment).
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4.3. Statistical Analysis
Continuous variables are presented as the arithmetic mean and standard deviation.
Qualitative variables are shown as percentages. Differences between groups were analysed
with the Chi-square test. Multivariate analysis was performed using a logistic regression
model by means of the stepwise forward likelihood method with H. pylori mITT eradication
as dependent variable and age, gender, treatment duration, PPI dose, compliance, and
previous use of clarithromycin as independent factors (this last one only in second-line
approaches). Significance was considered at p < 0.05.
4.4. Outcome Reporting
Analyses were performed separately in the global population, first- and second-line
therapy samples and penicillin-allergic patients. Effectiveness, safety and compliance were
evaluated in those patients receiving empirical therapies (not culture-guided) (Figure 2).
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5. Conclusions
In Spain, the standard triple therapy containing clarithromycin and amoxicillin shows
an inadequate effectiveness; therefore, its empirical use should be abandoned. The best
effectiveness in first-line was obtained with the bismuth single-capsule prescribed for
10 days, and the concomitant and bismuth-clarithromycin quadruple therapies, both
prescribed for 14 days. In second-line, the best effectiveness was obtained with a 10-day
bismuth single-capsule regimen, and also with 14-day quinolone-containing therapies,
either with or without bismuth. In general terms, we have seen a tendency over time
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towards the rise in the use of quadruple therapies, longer duration regimens and higher
doses of PPIs. This is in line with current recommendations by the main guidelines, which
are, slowly but steadily, being implemented by Spanish gastroenterologists in clinical
practice. These three factors, together with good compliance, seem to be, in general terms,
the four main strategies to increase effectiveness.
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